Sodium-glucose cotransporter 2 inhibitors (SGLT2is) are a class of newly introduced
antidiabetic drugs with potent hypoglycemic effects. Recent evidence suggests that these …

Several recent cardiovascular trials of SGLT 2 (sodium-glucose cotransporter 2) inhibitors
revealed that they could reduce adverse cardiovascular events in patients with T2DM (type 2 …

Overloaded glucose levels in several metabolic diseases such as type 2 diabetes (T2D) can
lead to mitochondrial dysfunction and enhanced production of reactive oxygen species …

Three cardiovascular outcome trials of sodium glucose cotransporter 2 (SGLT2) inhibitors,
including the EMPA-REG OUTCOME trial, CANVAS Program, and DECLARE TIMI 58 trial …

Therapy for diabetic kidney disease (DKD) is undergoing a revolution with the realization
that some glucose-lowering drugs have nephroprotective actions that may be intrinsic to the …

Mitochondria have an essential function in cell survival due to their role in bioenergetics,
reactive oxygen species generation, calcium buffering, and other metabolic activities …

The effects of intense glycaemic control on macrovascular complications in patients with
type 2 diabetes are incompletely resolved, and many glucose-lowering medications …

Empagliflozin, a sodium-glucose co-transporter 2 inhibitor developed, has been shown to
reduce cardiovascular events in patients with type 2 diabetes and established …

Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a new class of oral glucose-lowering
agents. Apart from their glucose-lowering effects, large clinical trials assessing certain …

Sodium-glucose transporter 2 inhibitors (SGLT2is) exert significant cardiovascular and heart
failure benefits in type 2 diabetes mellitus (DM) patients and can help reduce cardiac …